Evidence map›Paper›PMID 38623562›Full record

ArticleComputational and structural biotechnology journal2024

Structure-guided identification and characterization of potent inhibitors targeting PhoP and MtrA to combat mycobacteria.

Han-Li Su, Shu-Jung Lai, Keng-Chang Tsai, Kit-Man Fung, Tse-Lin Lung, Hsing-Mien Hsu, Yi-Chen Wu, Ching-Hui Liu, Hui-Xiang Lai, Jiun-Han Lin and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Han-Li SuDepartment of Emergency Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City 600, Taiwan.
Shu-Jung LaiGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Keng-Chang TsaiNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan.
Kit-Man FungBiomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 11529, Taiwan.
Tse-Lin LungInstitute of Molecular Biology, National Chung Hsing University, Taichung,Taiwan.
Hsing-Mien HsuInstitute of Molecular Biology, National Chung Hsing University, Taichung,Taiwan.
Yi-Chen WuInstitute of Molecular Biology, National Chung Hsing University, Taichung,Taiwan.
Ching-Hui LiuInstitute of Molecular Biology, National Chung Hsing University, Taichung,Taiwan.
Hui-Xiang LaiInstitute of Molecular Biology, National Chung Hsing University, Taichung,Taiwan.
Jiun-Han LinDepartment of Industrial Technology, Ministry of Economic Affairs, Taipei, Taiwan.
Tien-Sheng TsengInstitute of Molecular Biology, National Chung Hsing University, Taichung,Taiwan.
National Chung Hsing University · TWChia-Yi Christian Hospital · TWChina Medical University · TWInstitute of Biomedical Sciences, Academia Sinica · TWMinistry of Economic Affairs · TWNational Research Institute of Chinese Medicine · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycobacteria are causative agents of tuberculosis (TB), which is a global health concern. Drug-resistant TB strains are rapidly emerging, thereby necessitating the urgent development of new drugs. Two-component signal transduction systems (TCSs) are signaling pathways involved in the regulation of various bacterial behaviors and responses to environmental stimuli. Applying specific inhibitors of TCSs can disrupt bacterial signaling, growth, and virulence, and can help combat drug-resistant TB. We conducted a comprehensive pharmacophore-based inhibitor screening and biochemical and biophysical examinations to identify, characterize, and validate potential inhibitors targeting the response regulators PhoP and MtrA of mycobacteria. The constructed pharmacophore model Phar-PR-n4 identified effective inhibitors of formation of the PhoP-DNA complex: ST132 (IC

Indexed as

Drug-resistant tuberculosisMycobacteriaPharmacophore-based inhibitor screeningTuberculosisTwo-component signal transduction systems

Identifiers

PMID38623562
PMCPMC11016868
OpenAlexW4393852030

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.